SOAT1 and intracranial hemorrhage: Notably, using Ruxolitinib to inhibit the JAK-STAT pathway could significantly reduce the incidence of fusiform-like vascular dilatation and intracranial hemorrhages phenotypes induced by PDGFRB mutations, suggesting that this inhibitor was a promising option for targeted treatment of fusiform-like vascular dilatation such as fusiform aneurysms secondary to constitutive activation of PDGFRBY562D variants.